460 related articles for article (PubMed ID: 18256927)
1. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
2. Lack of RUNX3 inactivation in columnar cell lesions of breast.
Subramaniam MM; Chan JY; Omar MF; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Histopathology; 2010 Oct; 57(4):555-63. PubMed ID: 20955380
[TBL] [Abstract][Full Text] [Related]
3. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
4. RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis.
Subramaniam MM; Chan JY; Soong R; Ito K; Yeoh KG; Wong R; Guenther T; Will O; Chen CL; Kumarasinghe MP; Ito Y; Salto-Tellez M
Am J Gastroenterol; 2009 Feb; 104(2):426-36. PubMed ID: 19174785
[TBL] [Abstract][Full Text] [Related]
5. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
6. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
Schuetz CS; Bonin M; Clare SE; Nieselt K; Sotlar K; Walter M; Fehm T; Solomayer E; Riess O; Wallwiener D; Kurek R; Neubauer HJ
Cancer Res; 2006 May; 66(10):5278-86. PubMed ID: 16707453
[TBL] [Abstract][Full Text] [Related]
7. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
8. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
Moelans CB; Verschuur-Maes AH; van Diest PJ
J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
[TBL] [Abstract][Full Text] [Related]
9. Genetic pathways in the evolution of breast ductal carcinoma in situ.
Farabegoli F; Champeme MH; Bieche I; Santini D; Ceccarelli C; Derenzini M; Lidereau R
J Pathol; 2002 Mar; 196(3):280-6. PubMed ID: 11857490
[TBL] [Abstract][Full Text] [Related]
10. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Kominsky SL; Argani P; Korz D; Evron E; Raman V; Garrett E; Rein A; Sauter G; Kallioniemi OP; Sukumar S
Oncogene; 2003 Apr; 22(13):2021-33. PubMed ID: 12673207
[TBL] [Abstract][Full Text] [Related]
11. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
12. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
[TBL] [Abstract][Full Text] [Related]
13. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3.
Tan SH; Ida H; Lau QC; Goh BC; Chieng WS; Loh M; Ito Y
Oncol Rep; 2007 Nov; 18(5):1225-30. PubMed ID: 17914577
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
15. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines.
Ku JL; Kang SB; Shin YK; Kang HC; Hong SH; Kim IJ; Shin JH; Han IO; Park JG
Oncogene; 2004 Sep; 23(40):6736-42. PubMed ID: 15273736
[TBL] [Abstract][Full Text] [Related]
17. Genetic changes in intraductal breast cancer detected by comparative genomic hybridization.
Kuukasjärvi T; Tanner M; Pennanen S; Karhu R; Kallioniemi OP; Isola J
Am J Pathol; 1997 Apr; 150(4):1465-71. PubMed ID: 9095001
[TBL] [Abstract][Full Text] [Related]
18. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
[TBL] [Abstract][Full Text] [Related]
19. [Promoter methylation and expression of Runx3 gene in gastric cancer].
Li LY; Li JK; Shen Y; Yu L; Zhang JH
Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):379-82. PubMed ID: 18636364
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
